A Study of Pyridostigmine in Postural Tachycardia Syndrome

• Status: Recruiting
• Trial end date: 2022-02-01
• Target enrollment: 0
• Participant gender: All

Summary

This is a 3-day study comparing pyridostigmine versus placebo in the treatment of postural tachycardia syndrome (POTS). The researchers expect pyridostigmine to improve tachycardia and stabilize blood pressure.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Mayo Clinic
• Collaborator: National Institutes of Health (NIH)
• Treatments: Pyridostigmine Bromide

Criteria

Inclusion Criteria:

Diagnosis of postural tachycardia syndrome using the following criteria:

• Orthostatic heart rate increment greater than or equal to 30 beats per minute (bpm) within 5 minutes of head-up tilt.

• Symptoms of orthostatic intolerance. These include weakness, lightheadedness, blurred vision, nausea, palpitations, and difficulty with concentration and thinking.

Both criteria must be fulfilled.

Exclusion Criteria:

• Pregnant or lactating women

• Presence of failure of other organ systems or systemic illness that could affect autonomic function or the patient's ability to cooperate with the study

• Hypothyroidism or hyperthyroidism

• Clinically significant coronary artery disease

• Medications that could interfere with autonomic testing

• Previous treatment with pyridostigmine for POTS. Patients must not have taken pyridostigmine in the past month